Pancreatic Cancer Initial Detection Via Liquid Biopsy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pancreatic Cancer
- Sponsor
- Karolinska University Hospital
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Cancer detection
- Status
- Enrolling By Invitation
- Last Updated
- 2 years ago
Overview
Brief Summary
The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the aim to measure these markers in well-defined patient cohorts. For the entire series of these studies, the following groups are planned: 1) Histologically proven early-stage pancreatic cancer (e.g. T1a/b and T2 carcinomas [N0M0]); 2) Intraductal papillary mucinous neoplasia (IPMN) that were operated with verification of the benign, premalignant or malignant histology; 3) ordinary branched-duct IPMN; 4) individuals at risk (IAR) with and without IPMN, with and without known hereditary cancer gene (e.g. BRCA2); 5) a high risk group of patients with chronic pancreatitis, aged 55-65, who are heavy smokers (≥40 PY), with newly onset diabetes mellitus (NODM).
Investigators
Matthias Löhr
Professor of Gastroenterology & Hepatology
Karolinska University Hospital
Eligibility Criteria
Inclusion Criteria
- •Suspicion of or elevated risk for pancreatic ductal adenocarcinoma (PDAC); intraductal papillary mucinous neoplasias (IPMN); individuals at risk (IAR) for pancreatic cancer
Exclusion Criteria
- •other malignant condition
Outcomes
Primary Outcomes
Cancer detection
Time Frame: Up to 4 weeks after surgery
Liquid biopsy test(s) detecting pancreatic cancer on biobanked, archival samples of patients with histologically confirmed pancreatic lesions (PDAC, IPMN, pancreatitis).
Secondary Outcomes
- Overall survival(1 month - 24 months after surgical resection of the tumor)